NDAINTRAVENOUSSOLUTION
Approved
Jan 2015
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NEOSTIGMINE METHYLSULFATE (neostigmine methylsulfate) by Fresenius Kabi is action- neostigmine methylsulfate is a competitive cholinesterase inhibitor. First approved in 2015.
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Neostigmine methylsulfate is a competitive cholinesterase inhibitor administered intravenously as a solution. It reverses neuromuscular blockade by increasing acetylcholine in the synaptic cleft, competing for binding sites occupied by nondepolarizing neuromuscular blocking agents. This product is essential in perioperative anesthesia management.
Peak
Peak-stage product with stable institutional demand in perioperative settings; teams likely focused on market consolidation and operational efficiency rather than growth expansion.
Mechanism of Action
Action- Neostigmine methylsulfate is a competitive cholinesterase inhibitor. By reducing the breakdown of acetylcholine, neostigmine methylsulfate induces an increase in acetylcholine in the synaptic cleft which competes for the same binding site as nondepolarizing neuromuscular blocking agents,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on neostigmine methylsulfate offers a career in specialized institutional healthcare with stable, predictable demand in operating rooms and critical care units. This is a mature product suited for professionals focused on market access, formulary management, and operational excellence rather than innovation or commercial growth acceleration.
Hospital Account Manager
Worked on NEOSTIGMINE METHYLSULFATE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.